Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05725213Completed

ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis

Role: lead

NCT01618773Completed

Long-term Study of Epiduo in Patients With Moderate to Severe Acne

Role: lead

NCT02338544Completed

Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne

Role: lead

NCT01220102Completed

Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne

Role: lead

All 4 trials loaded